Skip to main content

Table 6 Total fatty acids of HBV cirrhosis patients in comparison of controls

From: Serum lipid profile as a marker of liver impairment in hepatitis B Cirrhosis patients

Fatty Acids (g/100 g) Controls Patients
C-14:0 1.00 ± 0.9 0.88 ± 0.7
C-16 : 0 18.01 ± 4.0 24.54 ± 3.4*
C-18 : 0 16.00 ± 4.6 15.77 ± 3.4
C-20 : 0 0.78 ± 0.6 0.21 ± 0.3*
C-24 : 0 0.02 ± 0.06 0.07 ± 0.2
C-14 : 1 0.17 ± 0.4 0.26 ± 0.4
C-16 : 1 2.03 ± 1.6 4.65 ± 0.7*
C-18 : 1 22.18 ± 4.8 23.70 ± 2.9
C-22 : 1 1.75 ± 1.4 1.38 ± 0.9
C-24 : 1 0.18 ± 0.5 ND
C-18 : 2 28.72 ± 3.3 22.75 ± 3.2*
C-18 : 3 0.59 ± 0.9 0.12 ± 0.3
C-20 : 3 1.35 ± 0.9 0.09 ± 0.1*
C-20 : 4 6.31 ± 1.0 3.57 ± 0.8*
C-20 : 5 0.71 ± 0.3 ND*
C-22 : 5 0.33 ± 0.6 0.87 ± 0.8
C-22 : 6 0.50 ± 0.6 0.51 ± 0.7
C-16 : 1: C-16 : 0 0.1 0.2
C-18 : 1: C-18 : 0 1.3 1.5
PUFA : SFA 1.5 0.6
  1. Values are mean ± standard deviation,* shows significant difference from HBV-cirrhosis patients with comparison of healthy controls a p < 0.05 (t-test). myristic acid (C14:0), myristoleic acid (C14:1), palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), α-linolenic acid (C18:3), arachidic acid (C20:0), eicosatrienoic acid (C-20:3), arachidonic acid (C20:4), eicosapentaenoic acid (EPA (C20:5), docosenoic acid (C22:1), docosahexaenoic acid (DHA (C22:6), nervonic acid(C24:1), not detected (ND)